Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Expansion of ResidenceTimer™ kinase panel
Determination of target residence time may help you to differentiate your drug candidate from competitor compounds. Drugs that [...]
Compound profiling on EGFR mutants and osimertinib-resistant cell lines
Mutations in the epidermal growth factor receptor (EGFR) are the most common oncogenic drivers in non-small cell lung [...]
Cancer cell panel profiling of MAPK pathway inhibitors
The MAPK signal transduction pathway plays a key role in tumor progression. Mutations in the corresponding driver genes, [...]
Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinibOncolines®2024-03-18T16:59:40+01:00
Case study – Target identification via Oncolines® profiling and ResidenceTimer™Oncolines®2024-07-04T09:50:44+02:00
Case study – Gene expression profiling to understand and combat drug resistancejanneke2023-05-29T15:56:23+02:00
Case study – Combination matrix to determine Bliss independence synergy scoresOncolines®2024-07-04T09:50:26+02:00
Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancerOncolines®2023-05-29T15:58:13+02:00
